Diagnosis & ScreeningResearch
Emerging Biomarker Research May Expand Options for Autism Recognition
From eye-tracking to microbiome analysis, new approaches aim to identify autism traits earlier — though validation and accessibility challenges remain.
Expanding Identification Approaches
Current autism identification typically occurs between ages 2-4 through behavioral observation, though recognition often comes later for girls and marginalized groups. Emerging research explores whether biological markers might help identify autism-related traits earlier. A 2024 study in Nature found certain urinary metabolites associated with gut bacteria differences in some autistic individuals, while eye-tracking research published in JAMA Network Open (May 2024) showed gaze patterns could help distinguish autistic children as young as 18 months.
Developing Technologies
Researchers are investigating multiple approaches:
A 2025 Frontiers in Psychiatry review notes that personalized approaches beginning before age 3 may help with communication development.
- Eye-tracking: Studies like those summarized in Contemporary Pediatrics (2026) suggest gaze patterns may offer early indicators
- Microbiome analysis: A Hong Kong team is preparing a pilot study of an AI-assisted stool test (CUHK announcement), though its claimed 95% accuracy lacks peer-reviewed verification
- Digital phenotyping: Research in Nature (2023) found movement patterns from wearable devices might help identify autism-related traits
Potential Benefits of Earlier Recognition
When support aligns with an individual's needs early in development, research suggests it can improve quality of life. A 2025 Frontiers in Psychiatry review notes that personalized approaches beginning before age 3 may help with communication development. However, experts emphasize that autism manifests differently across individuals, and support should focus on enabling thriving rather than 'normalization'.
Key Considerations
- No biomarker test is currently validated for standalone autism identification
- Autism's neurodiversity means single biomarkers are unlikely to capture its full spectrum
- Gut microbiome findings may reflect associated traits rather than autism itself (PMC review)
- Digital phenotyping requires careful privacy protections
- Earlier recognition must be paired with accessible, neurodiversity-affirming support
Sources
- 01Elevated microbially-derived metabolites in autism: a possible diagnostic screening test for a distinct ASD phenotype
- 02Eye-Tracking Biomarkers and Autism Diagnosis in Primary Care
- 03CUHK to pilot free AI-powered stool test for autism in children
- 04Early detection of autism using digital behavioral phenotyping - Nature
- 05Reduced false positives in autism screening via digital biomarkers inferred from deep comorbidity patterns
- 06Emerging biomarkers in autism spectrum disorder: a systematic review
Common questions
Behind the brief
Adversarial editorial review
Open thread